TL;DR
- Compliance Program Guidance Manuals (CPGMs) are FDA's internal instructions to its own field investigators, telling them what to inspect for and how, by product and program area (FDA: Compliance Program Guidance Manuals).
- Unlike a regulation, a CPGM isn't legally binding on industry — it's an operating instruction for FDA staff — but it directly shapes what an inspector actually looks for on-site.
- CPGMs are public documents, which means a regulatory affairs team can read the same instructions FDA gave its own investigators before an inspection.
- When FDA revises a CPGM, it's often a leading indicator of where inspection focus is shifting, sometimes well before that shift shows up in published enforcement statistics.
How FDA's Compliance Program Guidance Manuals Quietly Set Inspection Priorities
Ask a compliance officer what regulation governs a specific inspection focus area, and they'll usually cite a CFR part. Ask what tells the FDA investigator standing in the facility exactly what to check and how to document it, and the answer is often a document most companies never read: the Compliance Program Guidance Manual for that specific program area.
What a CPGM Actually Is
A Compliance Program Guidance Manual is FDA's internal operating document for a specific inspection or surveillance program — drug manufacturing inspections, biologics, medical devices, and dozens of other product and activity areas each have their own CPGM (FDA: Compliance Program Guidance Manuals). Unlike a CFR regulation, which is legally binding on industry, a CPGM is an instruction to FDA's own investigators and compliance staff — how to plan an inspection, what to sample, what documentation to review, and how to classify and report what they find.
Why This Matters Even Though It's Not Legally Binding on Industry
A CPGM doesn't create a new legal obligation for a manufacturer the way a regulation does. What it does is determine, in practice, what an inspector is instructed to look at and how thoroughly. Two facilities can be equally compliant with the underlying CFR requirements, but the one inspected under a more probing, more recently updated CPGM focus area is more likely to have something flagged, simply because the investigator was told to look harder in that specific place.
This is why regulatory affairs teams that track CPGM content and revision history alongside the underlying regulations get a more complete picture of actual inspection risk than teams that only track the regulations themselves.
CPGMs Are Public — and Worth Reading Before an Inspection, Not After
Because CPGMs are published documents, a firm preparing for an upcoming inspection can read the exact instructions FDA gave the investigator who's about to show up — what records they're expected to request, what sampling approach they're told to use, what specific compliance history they're instructed to review beforehand. Very few internal inspection-readiness programs build CPGM review into their preparation checklist, which is a missed opportunity given how directly the document maps to what actually happens during the visit.
Revisions Are a Leading Indicator
When FDA updates a CPGM, it's often responding to an internal assessment that inspection focus needs to shift — a new risk area, a pattern of findings the agency wants investigators to probe more systematically, or a response to a public health concern. Because CPGM revisions are published before their effects show up in aggregate enforcement statistics (which lag by the time it takes inspections to happen, get reviewed, and get reported), reading revision history is one of the more genuinely forward-looking signals available in FDA compliance monitoring, as opposed to backward-looking data like a prior year's Warning Letter counts.
How to Actually Use This
- Identify the CPGM (or manuals, if more than one program area applies) relevant to your facility type and product category.
- Compare the current version against the prior version, if archived copies are available, to see what changed in inspection scope or sampling instructions.
- Build any newly emphasized focus areas into your own internal audit program before, not after, your next scheduled inspection.
- Treat CPGM content as a checklist input alongside, not instead of, the underlying CFR requirements — a CPGM tells you what FDA is likely to check; the CFR still tells you what you're legally required to do.
FAQ
Are CPGMs the same as FDA guidance documents for industry?
No. FDA also publishes guidance documents aimed directly at industry, explaining the agency's current thinking on how to comply with a regulation. CPGMs are a distinct category, aimed at FDA's own investigators, describing how to conduct inspections and evaluate compliance.
Can a firm request a specific CPGM if it's not published online?
Most current CPGMs are published on FDA's website. For older or less commonly requested versions, a Freedom of Information Act request is generally the path if a document isn't already publicly posted.
Does every product category have its own CPGM?
FDA maintains CPGMs across a wide range of program areas — drugs, biologics, devices, foods, and more — though coverage and update frequency vary by program area based on FDA's own resource allocation and priorities.
Do CPGMs explain how FDA decides between NAI, VAI, and OAI classifications?
CPGMs generally describe the inspection process and what investigators are instructed to document, which feeds into the classification decision, but the classification framework itself (No Action Indicated, Voluntary Action Indicated, Official Action Indicated) is described separately in FDA's broader inspection policy guidance.
Related reading
- How to read your FDA inspection classification: NAI vs. VAI vs. OAI
- What Triggers an FDA For-Cause Inspection Versus a Routine Surveillance Inspection
- Why did FDA cite nine OTC drug manufacturers on three continents the same day?
Why compliance teams pick Argus →
Sources: FDA: Compliance Program Guidance Manuals, FDA Investigations Operations Manual (IOM), Chapter 5. Byline: The Argus Regulatory Analysis Team. Published 2026-07-16.